Uso de las terapias biológicas en las enfermedades autoinmunes sistémicas
Resultados
Resultados agrupados por enfermedad y agente biológico
EAS |
Agente biológico (retratamiento) |
Nº pacientes |
Respuesta terapéutica n (%) |
Efectos adversos n (%) |
Mortalidad
n (%) |
|---|---|---|---|---|---|
Behçet |
Infliximab |
6 |
4 (67%) |
0 (0%) |
0 (0%) |
Etanercep (2) |
3 |
2 (67%) |
1 (33%) |
0 (0%) |
|
Adalimumab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
Crioglobulinemia |
Rituximab |
4 |
4 (100%) |
0 (0%) |
1 (25%) |
Dermatomiositis |
Etanercept (1) |
3 |
2/2 (100%) |
1 (33%) |
0 (0%) |
Infliximab (1) |
2 |
1 (50%) |
2 (100%) |
0(0%) |
|
Rituximab |
3 |
2 (67%) |
0 (0%) |
1 (33%) |
|
Esclerodermia |
Rituximab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
LES |
Riuximab |
26 |
19/23 (83%) |
5 (19%) |
0 (0%) |
PAM |
Rituximab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
Etanercept |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
PAN |
Infliximab |
2 |
1 (50%) |
1 (50%) |
0 (0%) |
Adalimumab (1) |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
|
Rituximab (1) |
2 |
1 (100%) |
0 (0%) |
1 (50%) |
|
Policondritis |
Infliximab |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
Adalimumab |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
|
SAF |
Rituximab |
3 |
1 (33%) |
1 (33%) |
1 (33%) |
Sjögren |
Rituximab |
10 |
9 (100%) |
1 (10%) |
0 (0%) |
| Adalimubab | 1 |
1(100%) |
0(0%) |
0(0%) |
|
Still |
Infliximab |
3 |
3 (100%) |
1 (33%) |
0 (0%) |
Etanercept |
1 |
0(0%) |
0 (0%) |
0 (0%) |
|
Vogt-Koyanagi |
Infliximab |
1 |
0 (0%) |
0 (0%) |
0 (0%) |
Wegener |
Rituximab |
8 |
6 (75%) |
2 (25%) |
1 (12%) |
Etanercept (2) |
2 |
1 (50%) |
0 (0%) |
0 (0%) |
|
Artritis reactiva |
Adalimumab |
1 |
1 (100%) |
0 (0%) |
0 (0%) |
GN-VHC |
Rituximab |
1 |
0 (0%) |
1 (100%) |
1 (100%) |
ENFERMEDADES AUTOINMUNES SISTÉMICAS
(nº de pacientes tratados)
TERAPIAS BIOLÓGICAS ADMINISTRADAS
